Horizon Investment Services LLC Decreases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Horizon Investment Services LLC lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 57.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 905 shares of the medical research company’s stock after selling 1,221 shares during the period. Horizon Investment Services LLC’s holdings in Thermo Fisher Scientific were worth $367,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of TMO. Revolve Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Lafayette Investments Inc. raised its stake in Thermo Fisher Scientific by 2.4% in the second quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock valued at $376,000 after buying an additional 22 shares during the last quarter. Rossmore Private Capital grew its stake in shares of Thermo Fisher Scientific by 0.5% during the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock worth $2,315,000 after acquiring an additional 24 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH grew its position in Thermo Fisher Scientific by 3.1% during the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock worth $326,000 after purchasing an additional 24 shares during the last quarter. Finally, Somerville Kurt F increased its stake in Thermo Fisher Scientific by 1.6% during the 2nd quarter. Somerville Kurt F now owns 1,605 shares of the medical research company’s stock valued at $651,000 after purchasing an additional 25 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TMO shares. William Blair assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating on the stock. JPMorgan Chase & Co. increased their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Citigroup lifted their target price on Thermo Fisher Scientific from $500.00 to $580.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. UBS Group increased their price target on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Finally, TD Cowen lifted their price objective on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Nineteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $601.65.

Thermo Fisher Scientific Stock Performance

TMO opened at $566.47 on Friday. The stock has a market cap of $212.83 billion, a P/E ratio of 32.73, a P/E/G ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The firm has a fifty day moving average price of $516.99 and a 200 day moving average price of $461.35. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Thermo Fisher Scientific announced that its board has initiated a share buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, October 24th. The shares were sold at an average price of $574.15, for a total transaction of $229,660.00. Following the transaction, the executive vice president directly owned 21,152 shares of the company’s stock, valued at $12,144,420.80. This trade represents a 1.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 36,420 shares of company stock worth $19,980,884. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.